MX2019002669A - Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd). - Google Patents

Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).

Info

Publication number
MX2019002669A
MX2019002669A MX2019002669A MX2019002669A MX2019002669A MX 2019002669 A MX2019002669 A MX 2019002669A MX 2019002669 A MX2019002669 A MX 2019002669A MX 2019002669 A MX2019002669 A MX 2019002669A MX 2019002669 A MX2019002669 A MX 2019002669A
Authority
MX
Mexico
Prior art keywords
methods
neurological
disorders
mental disorders
behavioral symptoms
Prior art date
Application number
MX2019002669A
Other languages
English (en)
Inventor
M Fallon Joan
F Heil Matthew
Szigethy James
Nanus Kenneth
J Fallon James
Original Assignee
Curemark Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curemark Llc filed Critical Curemark Llc
Publication of MX2019002669A publication Critical patent/MX2019002669A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Closures For Containers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se describen aquí métodos para utilizar preparaciones de enzimas digestivas revestidas y sistemas de suministro de enzimas y composiciones farmacéuticas que comprenden las preparaciones para tratamiento de sujetos que tienen desórdenes de comportamiento, desórdenes neurológicos o desórdenes de salud mental. Aquí se describen métodos para tratar síntomas núcleo y no núcleo de desórdenes de comportamiento, desórdenes neurológicos o desórdenes de salud mental. También se describen aquí productos para uso en métodos de tratamiento y métodos para producir los mismos.
MX2019002669A 2012-01-03 2014-07-02 Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd). MX2019002669A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582813P 2012-01-03 2012-01-03
US201261600110P 2012-02-17 2012-02-17

Publications (1)

Publication Number Publication Date
MX2019002669A true MX2019002669A (es) 2019-05-30

Family

ID=48745413

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008156A MX363096B (es) 2012-01-03 2013-01-03 Composición farmacéutica para usarse en el tratamiento de la malnutrición en un sujeto que exhibe un trastorno de espectro de autismo (asd).
MX2019002669A MX2019002669A (es) 2012-01-03 2014-07-02 Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014008156A MX363096B (es) 2012-01-03 2013-01-03 Composición farmacéutica para usarse en el tratamiento de la malnutrición en un sujeto que exhibe un trastorno de espectro de autismo (asd).

Country Status (15)

Country Link
US (2) US20130224172A1 (es)
EP (1) EP2800581A4 (es)
JP (3) JP6796372B2 (es)
KR (3) KR20190109564A (es)
CN (2) CN104144698A (es)
AU (2) AU2013206890B2 (es)
BR (1) BR112014016557A8 (es)
CA (1) CA2862403C (es)
GB (1) GB2511713B (es)
HK (2) HK1201731A1 (es)
IL (1) IL233372B (es)
MX (2) MX363096B (es)
NZ (2) NZ716627A (es)
RU (1) RU2654230C2 (es)
WO (1) WO2013103746A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005192A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
KR20180015126A (ko) * 2015-04-14 2018-02-12 스티븐 호프만 자폐증을 치료하기 위한 조성물 및 방법
CN105213433A (zh) * 2015-11-06 2016-01-06 王益超 一种用于治疗孤独症、复发性流产和不孕症的组合物
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11547707B2 (en) * 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US20210043106A1 (en) * 2019-08-08 2021-02-11 COGNITIVEBOTICS Technologies Pvt. Ltd. Technology based learning platform for persons having autism
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN112347257A (zh) * 2020-11-11 2021-02-09 北京嘉和海森健康科技有限公司 一种患者症状口语化标准化方法和装置
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US6534063B1 (en) * 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6261613B1 (en) 2000-02-15 2001-07-17 General Mills, Inc. Refrigerated and shelf-stable bakery dough products
US6399114B2 (en) * 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
WO2002014537A2 (en) 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
DE10065123B4 (de) * 2000-12-28 2012-12-20 Robert Bosch Gmbh Verfahren zur Steuerung einer Diagnose eines Katalysators im Abgas eines Verbrennungsmotors
AU2002364750A1 (en) * 2001-12-14 2003-06-30 Solvay Pharmaceuticals Gmbh Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US20060115467A1 (en) * 2004-12-01 2006-06-01 Pangborn Jon B Compositions and methods for the treatment of autism
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
SI2523661T1 (sl) * 2010-01-15 2017-09-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Nkcc inhibitorji za zdravljenje avtizma

Also Published As

Publication number Publication date
AU2017232048A1 (en) 2017-10-12
EP2800581A1 (en) 2014-11-12
AU2017232048B2 (en) 2019-05-02
JP6810724B2 (ja) 2021-01-06
IL233372B (en) 2019-09-26
BR112014016557A2 (pt) 2017-06-13
CN104144698A (zh) 2014-11-12
NZ734194A (en) 2021-02-26
RU2014130165A (ru) 2016-02-27
JP6796372B2 (ja) 2020-12-09
CA2862403C (en) 2022-08-09
JP2019006788A (ja) 2019-01-17
BR112014016557A8 (pt) 2017-07-04
US20210162024A1 (en) 2021-06-03
GB201411821D0 (en) 2014-08-13
WO2013103746A1 (en) 2013-07-11
HK1201731A1 (en) 2015-09-11
US20130224172A1 (en) 2013-08-29
CN108578684A (zh) 2018-09-28
RU2654230C2 (ru) 2018-05-17
JP2021001222A (ja) 2021-01-07
HK1257360A1 (zh) 2019-10-18
NZ716627A (en) 2017-08-25
KR20140107665A (ko) 2014-09-04
JP2015503586A (ja) 2015-02-02
KR20200113029A (ko) 2020-10-05
AU2013206890A1 (en) 2014-07-24
AU2013206890B2 (en) 2017-09-28
KR102315761B1 (ko) 2021-10-20
EP2800581A4 (en) 2015-08-12
MX363096B (es) 2019-03-08
KR20190109564A (ko) 2019-09-25
IL233372A0 (en) 2014-08-31
GB2511713B (en) 2020-03-04
GB2511713A (en) 2014-09-10
CA2862403A1 (en) 2013-07-11
MX2014008156A (es) 2015-04-13
NZ737957A (en) 2021-07-30

Similar Documents

Publication Publication Date Title
MX2019002669A (es) Composicion farmaceutica para usarse en el tratamiento de la malnutricion en un sujeto que exhibe un trastorno de espectro de autismo (asd).
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
GB2480987B (en) Enzyme delivery systems and methods of preparations and use
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
WO2013061161A3 (en) New combination therapies for treating neurological disorders
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
PT2774991T (pt) Sistema de entrega de fármaco para utilização no tratamento ou diagnóstico de distúrbios neurológicos
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
WO2013038200A3 (en) Neurodevelopmental disorders
PH12020500472A1 (en) Autotaxin inhibitor compounds
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
UA100955C2 (ru) Производные оксазина и их применение в лечении неврологических расстройств